PRECiSE 2

PRECiSE 2, a randomized, treatment-withdrawal study, showed that patients who responded to induction therapy at Week 6 were more likely to have a maintained response and remission at 26 weeks with continued CIMZIA treatment than by switching to placebo¹

Learn more about:

Reference:

Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al. Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med. 2007;357:239-250.

Next: PRECiSE 2 Trial Design

Print this page

CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

For more information 1.866.4.CIMZIA

CIMZIA^®, CIMplicity™, CIMpay^® are trademarks of the UCB Group of Companies.

OXO, GOOD GRIPS, and the associated logos are trademarks of Helen of Troy Limited and are used under license.

Important Safety Information Regarding Fungal Infections

Unsubscribe

PRECiSE 2

PRECiSE 2, a randomized, treatment-withdrawal study, showed that patients who responded to induction therapy at Week 6 were more likely to have a maintained response and remission at 26 weeks with continued CIMZIA treatment than by switching to placebo1

PRECiSE 2, a randomized, treatment-withdrawal study, showed that patients who responded to induction therapy at Week 6 were more likely to have a maintained response and remission at 26 weeks with continued CIMZIA treatment than by switching to placebo¹